Cancer
Malignant Rectal Neoplasm
CI-CAN-00008012Explore in graph →
Top-level388 active trials1 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00008012Explore in graph →
Clinical trials
1,551 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (153)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05086627 | Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer | completed | Phase 2 | 118 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 |
| clinicaltrials |
| NCT00788957 | Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | completed | Phase 1 / Phase 2 | 177 | NantBioScience, Inc.INDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT04636008 | Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06455124 | Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06443671 | Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer(PKUCH-R09) | not yet recruiting | Phase 2 / Phase 3 | 132 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04755920 | SGM-101 in Colorectal Brain Metastases.(SGM-CBM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04205955 | Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors | completed | Phase 2 | 95 | SWOG Cancer Research NetworkNETWORK | 2 | May 1, 2024 | clinicaltrials |
| NCT06390982 | Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT05900648 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06255379 | Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 52 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT04124601 | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer(CHINOREC) | completed | Phase 2 | 80 | Johannes Laengle, MD, PhDOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05228431 | Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 121 | Zhen-Hai LuOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04543695 | A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer | unknown | Phase 2 | 255 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06304987 | Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | unknown | Phase 2 | 50 | Beijing Friendship HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06234007 | Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03951337 | 64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum) | unknown | Phase 2 | 70 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06304545 | Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab | not yet recruiting | Phase 2 | 48 | Harbin Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT05111860 | Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy | unknown | Phase 1 / Phase 2 | 20 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT00407654 | VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06266832 | The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma | recruiting | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06254521 | The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer | recruiting | Phase 2 | 60 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05980689 | Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03503630 | Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma | unknown | Phase 2 | 44 | Ali ShamseddineOTHER | 2 | Jan 31, 2024 | clinicaltrials |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 92 | Gilead SciencesINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05245474 | Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer | recruiting | Phase 2 | 186 | Beijing Friendship HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04558684 | Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer | suspended | Phase 1 / Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02363374 | Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer(CAOAROAIO-12) | completed | Phase 2 | 311 | Prof. Dr. med. Claus RödelOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03729687 | Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer(LARCT-US) | unknown | Phase 2 | 280 | Uppsala UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT00019760 | Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03840239 | TNT to Increase the Clinical Complete Response Rate for Distal LARC(TESS) | active not recruiting | Phase 2 | 98 | Sun Yat-sen UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02017704 | Chemoradiation or Brachytherapy for Rectal Cancer(CORRECT) | completed | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer | terminated | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05450029 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer(SILAR) | recruiting | Phase 2 | 51 | Yanhong DengOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03156036 | Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC | completed | Phase 2 | 64 | Asan Medical CenterOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06014944 | Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody(PMMR/MSS) | not yet recruiting | Phase 2 | 30 | Changhai HospitalOTHER | 0 | Aug 31, 2023 | clinicaltrials |
| NCT05957016 | Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer | unknown | Phase 2 | 90 | Third Military Medical UniversityOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05998122 | Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study | not yet recruiting | Phase 2 | 45 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05911789 | Online Adaptive Radiation Therapy for Rectal Cancer | unknown | Phase 1 / Phase 2 | 15 | Peking Union Medical College HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05969847 | Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer(TRACE-LE) | not yet recruiting | Phase 2 | 72 | 池畔OTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05939661 | A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer(AMBITION) | recruiting | Phase 2 | 45 | Osaka UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT04083365 | Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer(PANDORA) | unknown | Phase 2 | 100 | AUSL Romagna RiminiOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05868317 | Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer | unknown | Phase 2 | 70 | Salah Azaïz Cancer InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2024source: clinicaltrials